Guardian Pharmacy Services, Inc. (NYSE:GRDN – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $45.57.
Several equities research analysts recently commented on the company. KeyCorp initiated coverage on Guardian Pharmacy Services in a research note on Tuesday, September 22nd. They set an “overweight” rating and a $52.00 target price for the company. Oppenheimer increased their price target on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Truist Financial raised their price objective on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Weiss Ratings lowered shares of Guardian Pharmacy Services from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Finally, Wall Street Zen downgraded shares of Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research report on Sunday, October 25th.
Get Our Latest Report on Guardian Pharmacy Services
Institutional Investors Weigh In On Guardian Pharmacy Services
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. First Trust Advisors LP acquired a new position in shares of Guardian Pharmacy Services during the first quarter worth approximately $3,528,000. Dimensional Fund Advisors LP lifted its holdings in shares of Guardian Pharmacy Services by 200.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 208,594 shares of the company’s stock worth $7,855,000 after purchasing an additional 139,070 shares in the last quarter. Globeflex Capital L P acquired a new stake in Guardian Pharmacy Services in the 2nd quarter valued at $1,857,000. Bank of America Corp DE grew its position in Guardian Pharmacy Services by 86.1% in the 1st quarter. Bank of America Corp DE now owns 128,048 shares of the company’s stock valued at $4,822,000 after purchasing an additional 59,245 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in Guardian Pharmacy Services during the 1st quarter valued at $1,352,000.
Guardian Pharmacy Services Trading Up 10.3%
NYSE GRDN opened at $46.77 on Tuesday. The business’s 50-day moving average price is $41.61 and its two-hundred day moving average price is $38.39. Guardian Pharmacy Services has a 12 month low of $26.34 and a 12 month high of $48.33. The firm has a market capitalization of $2.33 billion, a PE ratio of 39.97, a price-to-earnings-growth ratio of 2.20 and a beta of 0.06.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. The company had revenue of $371.07 million for the quarter, compared to the consensus estimate of $365.76 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. As a group, analysts forecast that Guardian Pharmacy Services will post 1.18 earnings per share for the current fiscal year.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc provides pharmacy services to people living in long-term care and residential care settings. Its customers include assisted living and skilled nursing communities, behavioral health facilities, and other group-living providers.
The company supplies prescription medications and offers medication packaging, delivery, consulting, and clinical support. Its services are designed to help care providers manage residents’ medication needs and support continuity of care.
Founded in 2004, Guardian operates a network of pharmacies serving communities across the United States.
Further Reading
- Five stocks we like better than Guardian Pharmacy Services
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
